Home › Opko Health Submits Claros 1 Prostate Cancer Test, Immunoassay System for FDA Approval

Opko Health Submits Claros 1 Prostate Cancer Test, Immunoassay System for FDA Approval

Nov 07, 2017

NEW YORK (360Dx) – Opko Health today announced the filing of a premarket approval application with the US Food and Drug Administration for a total prostate-specific antigen test with the firm's Claros 1 immunoassay analyzer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Oct
23
Featured Webinar

Perspectives on Small RNA Sequencing: Challenges and Complications of Small RNA Library Prep

Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Clinical Lab Management

  1. New Roche Diagnostics Consultancy Aims to Partner With Labs on Improving Efficiency

    Premium

  2. ARUP Expansion to Increase Automation, Standardization and Processing Capacity

    Premium

  3. LabCorp Expands Number of Walgreens Patient Service Centers to at Least 600

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.